{"transactions":[{"id":4628452,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-10-03T01:00:55.000Z","date":"2026-09-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":76171,"price":36.57,"value":2785573.47,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":16583774,"source":{"system":"sec-edgar","filing":"0001140361-26-038475","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750094/000114036126038475/form4.xml","form_type":"4"}},{"id":717908,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-07-02T23:06:02.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":76171,"price":35.39,"value":2695691.69,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":16659945,"source":{"system":"sec-edgar","filing":"0001635088-26-000079","document":"wk-form4_1783033560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000079/wk-form4_1783033560.xml","form_type":"4"}},{"id":804417,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-04-20T22:27:23.000Z","date":"2026-04-16","kind":"sale","planned":false,"acquired":false,"shares":289774,"price":29.16,"value":8449809.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.98 to $29.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":16736116,"source":{"system":"sec-edgar","filing":"0001635088-26-000038","document":"wk-form4_1776724041.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000038/wk-form4_1776724041.xml","form_type":"4"}},{"id":822837,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2026-04-01T23:20:32.000Z","date":"2026-03-30","kind":"exercise","planned":false,"acquired":false,"shares":2178150,"price":11.5,"value":25048725.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Award of CVARs is fully vested."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026."}],"balance_after":0,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":97319},"source":{"system":"sec-edgar","filing":"0001635088-26-000034","document":"wk-form4_1775085629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000034/wk-form4_1775085629.xml","form_type":"4"}},{"id":822836,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-04-01T23:20:32.000Z","date":"2026-03-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":304684,"price":27.7,"value":8439746.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17025890,"source":{"system":"sec-edgar","filing":"0001635088-26-000034","document":"wk-form4_1775085629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000034/wk-form4_1775085629.xml","form_type":"4"}},{"id":822835,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-04-01T23:20:32.000Z","date":"2026-03-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":53826,"price":26.41,"value":1421544.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the \"net settlement\" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs."}],"balance_after":17330574,"source":{"system":"sec-edgar","filing":"0001635088-26-000034","document":"wk-form4_1775085629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000034/wk-form4_1775085629.xml","form_type":"4"}},{"id":822834,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2026-04-01T23:20:32.000Z","date":"2026-03-30","kind":"exercise","planned":false,"acquired":true,"shares":97319,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026."}],"balance_after":17384400,"source":{"system":"sec-edgar","filing":"0001635088-26-000034","document":"wk-form4_1775085629.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000034/wk-form4_1775085629.xml","form_type":"4"}},{"id":964998,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":2272852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.68,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":2272852},"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964997,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":1363711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.68,"expiration_date":"2026-03-31","underlying":"Common Stock","underlying_shares":1363711},"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964996,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":234096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Award of stock options to purchase Common Shares that is fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.06,"expiration_date":"2026-04-19","underlying":"Common Stock","underlying_shares":234096},"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964995,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":1329325,"price":21.68,"value":28819766.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934."}],"balance_after":17287081,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964994,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":943527,"price":21.68,"value":20455665.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934."}],"balance_after":18616406,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964993,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":2272852,"price":12.68,"value":28819763.36,"ownership":{"direct":true},"balance_after":19559933,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964992,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":797595,"price":21.68,"value":17291859.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934."}],"balance_after":17287081,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964991,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":566116,"price":21.68,"value":12273394.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934."}],"balance_after":18084676,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964990,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":1363711,"price":12.68,"value":17291855.48,"ownership":{"direct":true},"balance_after":18650792,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964989,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"other","planned":false,"acquired":false,"shares":3739,"price":21.68,"value":81061.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934."}],"balance_after":17287081,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964988,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":230357,"price":21.68,"value":4994139.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934."}],"balance_after":17290820,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":964987,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-12-18T02:00:09.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":234096,"price":4.06,"value":950429.76,"ownership":{"direct":true},"balance_after":17521177,"source":{"system":"sec-edgar","filing":"0001140361-25-045906","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125045906/form4.xml","form_type":"4"}},{"id":1036298,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-09-18T23:28:11.000Z","date":"2025-09-18","kind":"purchase","planned":false,"acquired":true,"shares":3315,"price":15.07,"value":49957.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range."}],"balance_after":17287081,"source":{"system":"sec-edgar","filing":"0001140361-25-035435","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125035435/form4.xml","form_type":"4"}},{"id":1137134,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-05-23T01:00:36.000Z","date":"2025-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":10945,"price":11.04,"value":120832.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17283766,"source":{"system":"sec-edgar","filing":"0001140361-25-020240","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125020240/form4.xml","form_type":"4"}},{"id":1167722,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-04-23T01:00:37.000Z","date":"2025-04-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":10945,"price":10.15,"value":111091.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17294711,"source":{"system":"sec-edgar","filing":"0001140361-25-014985","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125014985/form4.xml","form_type":"4"}},{"id":1193405,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-03-25T01:01:53.000Z","date":"2025-03-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":10945,"price":10.97,"value":120066.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17305656,"source":{"system":"sec-edgar","filing":"0001140361-25-010117","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125010117/form4.xml","form_type":"4"}},{"id":1249506,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-02-25T02:00:42.000Z","date":"2025-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":10945,"price":10.72,"value":117330.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17316601,"source":{"system":"sec-edgar","filing":"0001140361-25-005718","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125005718/form4.xml","form_type":"4"}},{"id":1297536,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2025-01-23T02:04:01.000Z","date":"2025-01-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":11623,"price":11.15,"value":129596.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17327546,"source":{"system":"sec-edgar","filing":"0001140361-25-001661","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125001661/form4.xml","form_type":"4"}},{"id":1321647,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-12-27T02:00:36.000Z","date":"2024-12-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":10945,"price":11.57,"value":126633.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17339169,"source":{"system":"sec-edgar","filing":"0001140361-24-050457","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124050457/form4.xml","form_type":"4"}},{"id":1354234,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-11-23T02:00:12.000Z","date":"2024-11-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":10945,"price":11.49,"value":125758.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17350114,"source":{"system":"sec-edgar","filing":"0001140361-24-047696","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124047696/form4.xml","form_type":"4"}},{"id":1382909,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-10-23T01:00:27.000Z","date":"2024-10-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":10945,"price":11.92,"value":130464.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":17361059,"source":{"system":"sec-edgar","filing":"0001140361-24-043960","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124043960/form4.xml","form_type":"4"}},{"id":1400112,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-25T01:01:02.000Z","date":"2024-09-23","kind":"exercise","planned":true,"acquired":false,"shares":1550000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":14973184,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Stock","underlying_shares":1550000},"source":{"system":"sec-edgar","filing":"0001140361-24-041788","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041788/form4.xml","form_type":"4"}},{"id":1400111,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-09-25T01:01:02.000Z","date":"2024-09-23","kind":"other","planned":true,"acquired":false,"shares":498539,"price":11.97,"value":5967511.83,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the \"net settlement\" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options."}],"balance_after":17372004,"source":{"system":"sec-edgar","filing":"0001140361-24-041788","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041788/form4.xml","form_type":"4"}},{"id":1400110,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-09-25T01:01:02.000Z","date":"2024-09-23","kind":"sale","planned":true,"acquired":false,"shares":1983257,"price":11.79,"value":23382600.03,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person does not expect to sell additional shares of the Issuer in the near future."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range."}],"balance_after":17870543,"source":{"system":"sec-edgar","filing":"0001140361-24-041788","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041788/form4.xml","form_type":"4"}},{"id":1400109,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-09-25T01:01:02.000Z","date":"2024-09-23","kind":"exercise","planned":true,"acquired":true,"shares":1550000,"price":3.85,"value":5967500.0,"ownership":{"direct":true},"balance_after":19853800,"source":{"system":"sec-edgar","filing":"0001140361-24-041788","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041788/form4.xml","form_type":"4"}},{"id":1400108,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-09-25T01:01:02.000Z","date":"2024-09-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":11.97,"value":131011.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":18303800,"source":{"system":"sec-edgar","filing":"0001140361-24-041788","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041788/form4.xml","form_type":"4"}},{"id":1425281,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-08-23T01:00:30.000Z","date":"2024-08-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10947,"price":11.48,"value":125671.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":18314745,"source":{"system":"sec-edgar","filing":"0001140361-24-038305","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124038305/form4.xml","form_type":"4"}},{"id":1446238,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-07-31T01:04:02.000Z","date":"2024-07-26","kind":"grant","planned":false,"acquired":true,"shares":14450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an award of performance restricted stock units with respect to Common Shares (\"PSUs\") across six share price hurdle tranches, as follows: $15.00 (14.71% of PSUs); $17.50 (7.35% of PSUs); $20.00 (8.82% of PSUs); $22.50 (11.77% of PSUs); $25.00 (22.06% ofPSUs); and $30.00 (35.29% of PSUs). The PSUs will vest tranche-by-tranche on the first date that both the performance condition and the service condition with respect to the applicable tranche of the PSUs has been satisfied. The performance condition will be deemed satisfiedfor each tranche of PSUs on the first date, during the performance period ending on the five-year anniversary of the grant date, when the Company's trailing 30-day volume weighted average trading price per share exceeds the share price hurdle applicable to such tranche (asspecified above)."},{"field":"shares","element":"transactionShares","label":"F3","text":"The service condition will be deemed satisfied for each tranche of PSUs on the first anniversary of the date on which the performance condition is first satisfied with respect to such tranche, subject to the reporting person's continuous service through such anniversary. Inaddition, following the satisfaction of the performance condition and service condition and the vesting of any tranche of the PSUs, the common shares underlying the applicable vested tranche of PSUs are subject to a further two-year holding period before such common sharesmay be sold."}],"balance_after":18325692,"source":{"system":"sec-edgar","filing":"0000950103-24-011231","document":"dp2015708_4-gline.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000095010324011231/dp2015708_4-gline.xml","form_type":"4"}},{"id":1446237,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-07-31T01:04:02.000Z","date":"2024-07-26","kind":"grant","planned":false,"acquired":true,"shares":2754821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock units with respect to Common Shares (\"RSUs\"), with a vesting commencement date of March 31, 2025, which service-vest (i) 20% on the first anniversary of the vesting commencement date and (ii) in 16 successive equal quarterly installments thereafter, subject to the reporting person's continuous service through the applicable vesting date."}],"balance_after":3875692,"source":{"system":"sec-edgar","filing":"0000950103-24-011231","document":"dp2015708_4-gline.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000095010324011231/dp2015708_4-gline.xml","form_type":"4"}},{"id":1448666,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-07-26T01:00:57.000Z","date":"2024-07-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":11,"value":120395.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1120871,"source":{"system":"sec-edgar","filing":"0001140361-24-034284","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124034284/form4.xml","form_type":"4"}},{"id":1470659,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-06-25T01:00:32.000Z","date":"2024-06-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":10.8,"value":118206.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1131816,"source":{"system":"sec-edgar","filing":"0001140361-24-031173","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124031173/form4.xml","form_type":"4"}},{"id":1505447,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-05-23T01:01:26.000Z","date":"2024-05-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":11.37,"value":124444.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1142761,"source":{"system":"sec-edgar","filing":"0001140361-24-027206","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124027206/form4.xml","form_type":"4"}},{"id":1536846,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-04-24T01:01:03.000Z","date":"2024-04-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":10.46,"value":114484.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1153706,"source":{"system":"sec-edgar","filing":"0001140361-24-021495","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124021495/form4.xml","form_type":"4"}},{"id":1553503,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2024-04-03T01:00:27.000Z","date":"2024-03-30","kind":"exercise","planned":true,"acquired":false,"shares":994373,"price":6.4,"value":6363987.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 30, 2024, the \"knock-in\" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On March 30, 2024, the \"knock-in\" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 30, 2024, the \"knock-in\" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 30, 2024, the \"knock-in\" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On March 30, 2024, the \"knock-in\" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024."}],"balance_after":0,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":390579},"source":{"system":"sec-edgar","filing":"0001140361-24-017373","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124017373/form4.xml","form_type":"4"}},{"id":1553502,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-04-03T01:00:27.000Z","date":"2024-03-30","kind":"tax_withholding","planned":true,"acquired":false,"shares":215991,"price":10.54,"value":2276545.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the \"net settlement\" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs."}],"balance_after":1164651,"source":{"system":"sec-edgar","filing":"0001140361-24-017373","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124017373/form4.xml","form_type":"4"}},{"id":1553501,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-04-03T01:00:27.000Z","date":"2024-03-30","kind":"exercise","planned":true,"acquired":true,"shares":390579,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 30, 2024, the \"knock-in\" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 30, 2024, the \"knock-in\" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024."}],"balance_after":1380642,"source":{"system":"sec-edgar","filing":"0001140361-24-017373","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124017373/form4.xml","form_type":"4"}},{"id":1563327,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-03-23T01:00:45.000Z","date":"2024-03-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":10.01,"value":109559.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":990063,"source":{"system":"sec-edgar","filing":"0001140361-24-014894","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124014894/form4.xml","form_type":"4"}},{"id":1625343,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-02-23T02:01:02.000Z","date":"2024-02-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":11.54,"value":126305.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1001008,"source":{"system":"sec-edgar","filing":"0001140361-24-009096","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124009096/form4.xml","form_type":"4"}},{"id":1672996,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2024-01-24T02:00:27.000Z","date":"2024-01-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":10.35,"value":113280.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1011953,"source":{"system":"sec-edgar","filing":"0001140361-24-003550","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124003550/form4.xml","form_type":"4"}},{"id":1697929,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2023-12-30T02:00:23.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":false,"shares":47351,"price":11.5,"value":544536.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"shares","element":"transactionShares","label":"F5","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."}],"balance_after":2178150,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":327},"source":{"system":"sec-edgar","filing":"0001140361-23-060293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123060293/form4.xml","form_type":"4"}},{"id":1697928,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2023-12-30T02:00:23.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":false,"shares":85232,"price":6.4,"value":545484.8,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"shares","element":"transactionShares","label":"F5","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":994373,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":38126},"source":{"system":"sec-edgar","filing":"0001140361-23-060293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123060293/form4.xml","form_type":"4"}},{"id":1697927,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-12-30T02:00:23.000Z","date":"2023-12-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":22043,"price":11.58,"value":255257.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the \"net settlement\" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs."}],"balance_after":1022898,"source":{"system":"sec-edgar","filing":"0001140361-23-060293","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123060293/form4.xml","form_type":"4"}},{"id":1697926,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-12-30T02:00:23.000Z","date":"2023-12-27","kind":"exercise","planned":true,"acquired":true,"shares":38453,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 85,232 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 38,126 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On December 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 327 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on December 27, 2023."}],"balance_after":1044941,"source":{"system":"sec-edgar","filing":"0001140361-23-060293","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123060293/form4.xml","form_type":"4"}},{"id":1700893,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-12-23T00:00:23.000Z","date":"2023-12-20","kind":"tax_withholding","planned":true,"acquired":false,"shares":10945,"price":9.96,"value":109012.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1006488,"source":{"system":"sec-edgar","filing":"0001140361-23-059240","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123059240/form4.xml","form_type":"4"}},{"id":1729495,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-11-28T02:30:18.000Z","date":"2023-11-22","kind":"other","planned":true,"acquired":false,"shares":11318,"price":8.68,"value":98240.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1017433,"source":{"system":"sec-edgar","filing":"0001140361-23-054757","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123054757/form4.xml","form_type":"4"}},{"id":1754710,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-10-27T01:30:27.000Z","date":"2023-10-24","kind":"other","planned":true,"acquired":false,"shares":12489,"price":8.99,"value":112276.11,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1028751,"source":{"system":"sec-edgar","filing":"0001140361-23-049763","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123049763/form4.xml","form_type":"4"}},{"id":1771502,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2023-09-30T01:30:37.000Z","date":"2023-09-27","kind":"exercise","planned":false,"acquired":false,"shares":47351,"price":11.5,"value":544536.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 4,236 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 4,236 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"shares","element":"transactionShares","label":"F6","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 4,236 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 4,236 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 4,236 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."}],"balance_after":2225501,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":4236},"source":{"system":"sec-edgar","filing":"0001140361-23-046108","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123046108/form4.xml","form_type":"4"}},{"id":1771501,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2023-09-30T01:30:37.000Z","date":"2023-09-27","kind":"exercise","planned":false,"acquired":false,"shares":28411,"price":6.4,"value":181830.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 28,411 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 13,526 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 28,411 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 13,526 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"shares","element":"transactionShares","label":"F6","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 28,411 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 13,526 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 28,411 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 13,526 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 28,411 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 13,526 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":1164836,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":13526},"source":{"system":"sec-edgar","filing":"0001140361-23-046108","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123046108/form4.xml","form_type":"4"}},{"id":1771500,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-09-30T01:30:37.000Z","date":"2023-09-28","kind":"other","planned":false,"acquired":false,"shares":10243,"price":12.67,"value":129778.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's \"sell to cover\" policy and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.25 to $13.20, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."}],"balance_after":1041240,"source":{"system":"sec-edgar","filing":"0001140361-23-046108","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123046108/form4.xml","form_type":"4"}},{"id":1771499,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-09-30T01:30:37.000Z","date":"2023-09-27","kind":"exercise","planned":false,"acquired":true,"shares":17762,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 28,411 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 13,526 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 4,236 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the \"CVAR Amount\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to 28,411 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 13,526 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 27, 2023, the hurdle price applicable to 47,351 of these vested CVARs has been satisfied and, accordingly, the CVARs were settled into 4,236 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on September 27, 2023."}],"balance_after":1051483,"source":{"system":"sec-edgar","filing":"0001140361-23-046108","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123046108/form4.xml","form_type":"4"}},{"id":1773300,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-09-27T01:30:42.000Z","date":"2023-09-22","kind":"other","planned":false,"acquired":false,"shares":11227,"price":10.19,"value":114403.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1033721,"source":{"system":"sec-edgar","filing":"0001140361-23-045329","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123045329/form4.xml","form_type":"4"}},{"id":1794194,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2023-08-30T01:31:30.000Z","date":"2023-05-27","kind":"exercise","planned":false,"acquired":false,"shares":28410,"price":6.4,"value":181824.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of 28,410 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of 28,410 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 28,410 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of 28,410 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of 28,410 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":1193247,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":12088},"source":{"system":"sec-edgar","filing":"0001140361-23-041708","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123041708/form4.xml","form_type":"4"}},{"id":1794193,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-08-30T01:31:30.000Z","date":"2023-08-28","kind":"other","planned":false,"acquired":false,"shares":6784,"price":11.25,"value":76320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's \"sell to cover\" policy and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.08 to $11.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":1044948,"source":{"system":"sec-edgar","filing":"0001140361-23-041708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123041708/form4.xml","form_type":"4"}},{"id":1794192,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-08-30T01:31:30.000Z","date":"2023-08-27","kind":"exercise","planned":false,"acquired":true,"shares":12088,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of 28,410 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 28,410 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On August 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 12,088 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on August 25, 2023."}],"balance_after":1051732,"source":{"system":"sec-edgar","filing":"0001140361-23-041708","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123041708/form4.xml","form_type":"4"}},{"id":1797696,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-08-25T01:30:31.000Z","date":"2023-08-22","kind":"other","planned":false,"acquired":false,"shares":11015,"price":10.83,"value":119292.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1039644,"source":{"system":"sec-edgar","filing":"0001140361-23-041197","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123041197/form4.xml","form_type":"4"}},{"id":1816358,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-08-04T01:30:45.000Z","date":"2023-08-02","kind":"other","planned":false,"acquired":false,"shares":11749,"price":11.79,"value":138520.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to the vested CVARs was satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023. This sale was effected pursuant to the issuer's \"sell to"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.79 to $11.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1050659,"source":{"system":"sec-edgar","filing":"0001140361-23-037942","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123037942/form4.xml","form_type":"4"}},{"id":1820449,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2023-08-01T01:33:05.000Z","date":"2023-07-27","kind":"exercise","planned":false,"acquired":false,"shares":56821,"price":6.4,"value":363654.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":1136426,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":23149},"source":{"system":"sec-edgar","filing":"0001140361-23-037133","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123037133/form4.xml","form_type":"4"}},{"id":1820448,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-08-01T01:33:05.000Z","date":"2023-07-27","kind":"exercise","planned":false,"acquired":true,"shares":23149,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 56,821 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On July 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 23,149 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on July 27, 2023."}],"balance_after":1062408,"source":{"system":"sec-edgar","filing":"0001140361-23-037133","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123037133/form4.xml","form_type":"4"}},{"id":1822812,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-07-27T01:30:19.000Z","date":"2023-07-24","kind":"other","planned":false,"acquired":false,"shares":11146,"price":10.99,"value":122494.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1039259,"source":{"system":"sec-edgar","filing":"0001140361-23-036310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123036310/form4.xml","form_type":"4"}},{"id":1844196,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-06-27T01:31:11.000Z","date":"2023-06-22","kind":"other","planned":false,"acquired":false,"shares":10863,"price":10.01,"value":108738.63,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1050405,"source":{"system":"sec-edgar","filing":"0001140361-23-031548","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031548/form4.xml","form_type":"4"}},{"id":1873321,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Capped Value Appreciation Rights","published_at":"2023-06-01T01:30:39.000Z","date":"2023-05-27","kind":"exercise","planned":false,"acquired":false,"shares":170464,"price":6.4,"value":1090969.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the conversion of 170,464 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 53,281 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the conversion of 170,464 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 53,281 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 170,464 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 53,281 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the conversion of 170,464 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 53,281 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects the conversion of 170,464 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 53,281 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This award of CVARs vests (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. In the event the fair market value of a Common Share is less than $9.20 per share as of the relevant date of determination (the \"knock-in condition\"), this award of CVARs will remain outstanding unless and until the knock-in condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs."}],"balance_after":1193247,"derivative":{"expiration_date":"2026-03-31","underlying":"Common Shares","underlying_shares":53281},"source":{"system":"sec-edgar","filing":"0001140361-23-027616","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123027616/form4.xml","form_type":"4"}},{"id":1873320,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-06-01T01:30:39.000Z","date":"2023-05-31","kind":"other","planned":false,"acquired":false,"shares":30266,"price":9.09,"value":275117.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This sale was effected pursuant to the issuer's \"sell to cover\" policy and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.95 to $9.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":1061268,"source":{"system":"sec-edgar","filing":"0001140361-23-027616","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123027616/form4.xml","form_type":"4"}},{"id":1873319,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-06-01T01:30:39.000Z","date":"2023-05-27","kind":"exercise","planned":false,"acquired":true,"shares":53281,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the conversion of 170,464 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 53,281 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the conversion of 170,464 capped value appreciation rights (\"CVARs\") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price of $6.40 per share (such excess, the \"CVAR Amount\"). On May 27, 2023, the \"knock-in\" condition (as defined below) and hurdle price applicable to these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 53,281 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on May 26, 2023."}],"balance_after":1091534,"source":{"system":"sec-edgar","filing":"0001140361-23-027616","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123027616/form4.xml","form_type":"4"}},{"id":1878082,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-05-26T01:31:06.000Z","date":"2023-05-23","kind":"other","planned":false,"acquired":false,"shares":18972,"price":9.58,"value":181751.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1038253,"source":{"system":"sec-edgar","filing":"0001140361-23-026781","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123026781/form4.xml","form_type":"4"}},{"id":1914883,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-04-25T01:28:19.000Z","date":"2023-04-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":19375,"price":8.8,"value":170500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1057225,"source":{"system":"sec-edgar","filing":"0001140361-23-019993","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123019993/form4.xml","form_type":"4"}},{"id":1937875,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-03-28T01:30:32.000Z","date":"2023-03-23","kind":"other","planned":false,"acquired":false,"shares":18563,"price":7.3,"value":135509.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1076600,"source":{"system":"sec-edgar","filing":"0001140361-23-014077","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123014077/form4.xml","form_type":"4"}},{"id":1993180,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-02-25T02:30:40.000Z","date":"2023-02-22","kind":"other","acquired":false,"shares":14471,"price":8.43,"value":121990.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4"}],"balance_after":1095163,"source":{"system":"sec-edgar","filing":"0001140361-23-008666","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123008666/form4.xml","form_type":"4"}},{"id":2044988,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2023-01-27T02:01:21.000Z","date":"2023-01-24","kind":"other","acquired":false,"shares":15594,"price":8.56,"value":133484.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4"}],"balance_after":1109634,"source":{"system":"sec-edgar","filing":"0001140361-23-002960","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123002960/form4.xml","form_type":"4"}},{"id":2075514,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-12-29T02:31:46.000Z","date":"2022-12-23","kind":"other","acquired":false,"shares":19408,"price":7.1,"value":137796.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4"}],"balance_after":1125228,"source":{"system":"sec-edgar","filing":"0001140361-22-047271","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122047271/form4.xml","form_type":"4"}},{"id":2106894,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-11-22T23:31:40.000Z","date":"2022-11-20","kind":"other","acquired":false,"shares":19373,"price":5,"value":96865.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1144636,"source":{"system":"sec-edgar","filing":"0001140361-22-042830","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122042830/form4.xml","form_type":"4"}},{"id":2130992,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-10-27T22:00:42.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":19276,"price":4.4,"value":84814.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1164009,"source":{"system":"sec-edgar","filing":"0001140361-22-038695","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122038695/form4.xml","form_type":"4"}},{"id":2150499,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-09-27T23:00:34.000Z","date":"2022-09-23","kind":"sale","acquired":false,"shares":21053,"price":3.07,"value":64632.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1183285,"source":{"system":"sec-edgar","filing":"0001140361-22-034881","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122034881/form4.xml","form_type":"4"}},{"id":2172854,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-08-26T23:00:32.000Z","date":"2022-08-24","kind":"sale","acquired":false,"shares":20009,"price":3.71,"value":74233.39,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1204338,"source":{"system":"sec-edgar","filing":"0000899243-22-029891","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322029891/doc4.xml","form_type":"4"}},{"id":2201335,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-07-28T01:08:26.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":20455,"price":4.33,"value":88570.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1224347,"source":{"system":"sec-edgar","filing":"0000899243-22-026925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322026925/doc4.xml","form_type":"4"}},{"id":2221127,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-06-27T23:00:25.000Z","date":"2022-06-23","kind":"sale","acquired":false,"shares":19855,"price":4.34,"value":86170.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1244802,"source":{"system":"sec-edgar","filing":"0000899243-22-024240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322024240/doc4.xml","form_type":"4"}},{"id":2258259,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-05-24T23:00:23.000Z","date":"2022-05-20","kind":"sale","acquired":false,"shares":139791,"price":3.7,"value":517226.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1264657,"source":{"system":"sec-edgar","filing":"0000899243-22-019397","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322019397/doc4.xml","form_type":"4"}},{"id":2289617,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-04-27T23:00:19.000Z","date":"2022-04-25","kind":"sale","acquired":false,"shares":8509,"price":3.84,"value":32674.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1404448,"source":{"system":"sec-edgar","filing":"0000899243-22-015797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322015797/doc4.xml","form_type":"4"}},{"id":2291821,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-22T23:25:30.000Z","date":"2022-04-20","kind":"grant","acquired":true,"shares":16523184,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":16523184,"derivative":{"exercise_price":3.85,"expiration_date":"2032-04-19","underlying":"Common Shares","underlying_shares":16523184},"source":{"system":"sec-edgar","filing":"0000899243-22-015518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322015518/doc4.xml","form_type":"4"}},{"id":2311207,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-04-01T22:00:16.000Z","date":"2022-03-30","kind":"tax_withholding","acquired":false,"shares":25254,"price":4.74,"value":119703.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":1412957,"source":{"system":"sec-edgar","filing":"0000899243-22-013164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322013164/doc4.xml","form_type":"4"}},{"id":2311206,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-04-01T22:00:16.000Z","date":"2022-03-30","kind":"sale","acquired":false,"shares":33686,"price":4.84,"value":163040.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1438211,"source":{"system":"sec-edgar","filing":"0000899243-22-013164","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322013164/doc4.xml","form_type":"4"}},{"id":2315330,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-03-29T22:29:26.000Z","date":"2022-03-25","kind":"sale","acquired":false,"shares":35386,"price":5.06,"value":179053.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1471897,"source":{"system":"sec-edgar","filing":"0000899243-22-012701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322012701/doc4.xml","form_type":"4"}},{"id":2321387,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-03-23T01:00:26.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":82006,"price":5.13,"value":420690.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1507283,"source":{"system":"sec-edgar","filing":"0000899243-22-011863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322011863/doc4.xml","form_type":"4"}},{"id":2341828,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":32850,"kind":"person","name":"Gline Matthew","position":1,"cik":"0001750094","reported_name":"Gline Matthew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Shares","published_at":"2022-03-10T02:45:18.000Z","date":"2022-03-07","kind":"sale","acquired":false,"shares":92324,"price":5.52,"value":509628.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":1589289,"source":{"system":"sec-edgar","filing":"0000899243-22-010363","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322010363/doc4.xml","form_type":"4"}}]}